Reuters logo
BRIEF-Seattle Genetics submits supplemental license application for Adcetris
November 2, 2017 / 12:12 PM / 22 days ago

BRIEF-Seattle Genetics submits supplemental license application for Adcetris

Nov 2 (Reuters) - Seattle Genetics Inc

* Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below